Ensifentrine Impurity, identified by the CAS number 3067475-19-5, is a chemical compound that is typically associated with the pharmaceutical development of ensifentrine, a dual inhibitor of the enzymes dipeptidyl peptidase I (DPP-I) and neutral endopeptidase (NEP). While specific characteristics of this impurity may not be widely documented, impurities in pharmaceutical compounds generally arise during synthesis or storage and can affect the efficacy and safety of the final product. Common characteristics of such impurities include variations in molecular weight, solubility, and reactivity compared to the parent compound. Ensifentrine itself is known for its potential therapeutic applications in respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). The presence of impurities like Ensifentrine Impurity necessitates rigorous quality control measures during drug formulation to ensure compliance with regulatory standards and to maintain the integrity of the therapeutic agent. Understanding the properties and behavior of impurities is crucial for pharmaceutical development and safety assessments.

Ensifentrine Impurity

3067475-19-5: Ensifentrine Impurity, identified by the CAS number 3067475-19-5, is a chemical compound that is typically associated with the pharmaceutical development of ensifentrine, a dual inhibitor of the enzymes dipeptidyl peptidase I (DPP-I) and neutral endopeptidase (NEP). While specific characteristics of this impurity may not be widely documented, impurities in pharmaceutical compounds generally arise during synthesis or storage and can affect the efficacy and safety of the final product. Common characteristics of such impurities include variations in molecular weight, solubility, and reactivity compared to the parent compound. Ensifentrine itself is known for its potential therapeutic applications in respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). The presence of impurities like Ensifentrine Impurity necessitates rigorous quality control measures during drug formulation to ensure compliance with regulatory standards and to maintain the integrity of the therapeutic agent. Understanding the properties and behavior of impurities is crucial for pharmaceutical development and safety assessments.

CAS 3067475-19-5

Ensifentrine Impurity

Ensifentrine Impurity 2

Ref: 4Z-E-225006

10-Hydroxy Ensifentrine Impurity

Ref: ST-EA-CP-E78001